Risk factor
Very high price volatility
Profitability factor
Strong growth
About
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of RXRX is 7.0 and suggests 89% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell